Brivaracetam

#	Item
1	U.S. FDA approves UCB’s new epilepsy treatment, BRIVIACT®, for patients with partial-onset seizures • BRIVIACT® (brivaracetam), a new molecular entity, is indicated as adjunctive therapy in the treatment of partial Add to Reading List Source URL: www.ucb-usa.com Language: English - Date: 2016-02-29 16:05:30 Medicine Clinical medicine Anticonvulsants Health GABAA receptor positive allosteric modulators Sodium channel blockers Epilepsy RTT Epileptic seizure Lorazepam Phenytoin Brivaracetam
2	UCB files VIMPAT® (lacosamide) in the US as monotherapy treatment in adult epilepsy patients with partial-onset seizures Add to Reading List Source URL: www.ucb-usa.com Language: English - Date: 2016-02-29 14:28:49 Anticonvulsants GABAA receptor positive allosteric modulators Epilepsy Sodium channel blockers Ethers Lacosamide Brivaracetam Benzodiazepine Clobazam Lamotrigine
3	Classification Status of Racetams Reason for Submission The Ministry of Health has received numerous queries regarding the regulatory position of products used for cognitive enhancement (also referred to as smart-drugs Add to Reading List Source URL: www.medsafe.govt.nz Language: English - Date: 2015-02-16 22:35:27 Piracetam Pramiracetam Brivaracetam Coluracetam Oxiracetam Etiracetam Aniracetam Nootropic Levetiracetam Racetams Chemistry Organic chemistry